Literature DB >> 9467524

Allogeneic versus autologous blood during abdominal aortic aneurysm surgery.

J I Spark1, I C Chetter, R C Kester, D J Scott.   

Abstract

OBJECTIVES: To determine if cell-salvaged autologous blood can serve as an alternative to homologous blood, and to examine the incidence of infected complications and length of postoperative stay.
DESIGN: A prospective randomised study comprising autologous and homologous blood transfusions in patients undergoing elective infrarenal abdominal aortic surgery.
METHODS: Fifty patients undergoing AAA surgery were prospectively randomised to homologous blood (n = 27), or autologous blood transfusion (n = 23), using a cell salvage autotransfusion device.
RESULTS: The haemoglobin at the time of hospital discharge was similar for both groups (11.0 vs. 10.8 g/dl) with no difference in perioperative mortality. The length of stay was reduced in those patients who received autologous blood (9 days vs. 12 days, p < 0.05 Mann-Whitney U test). There were four infected cases in the autologous group and 12 in the homologous group (p = n.s., Fisher's exact probability test). However, patients who received 3-4 units of homologous blood had an increased risk of infection compared to those who received a similar amount of autologous blood (50% vs. 0%).
CONCLUSIONS: Cell salvage autologous blood can safely replace, or at least decrease, exposure to homologous blood transfusion, with a reduction in the mean hospital stay.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9467524     DOI: 10.1016/s1078-5884(97)80128-1

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  8 in total

1.  Autologous versus allogeneic transfusion in aortic surgery: a multicenter randomized clinical trial.

Authors:  Julian C L Wong; Francesco Torella; Sarah L Haynes; Kirsteen Dalrymple; Andrew J Mortimer; Charles N McCollum
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

Review 2.  Cell salvage for minimising perioperative allogeneic blood transfusion.

Authors:  Paul A Carless; David A Henry; Annette J Moxey; Dianne O'Connell; Tamara Brown; Dean A Fergusson
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

3.  Transfusion requirements and outcomes in patients undergoing abdominal aortic surgery using intra-operative cell salvage.

Authors:  C F Healy; M Doyle; B Egan; B Hendrick; M K O'Malley; M K O'Donohoe
Journal:  Ir J Med Sci       Date:  2007-03       Impact factor: 1.568

4.  Recommendations for the transfusion management of patients in the peri-operative period. II. The intra-operative period.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2011-04       Impact factor: 3.443

5.  Effects of transfusion with red cells filtered to remove leucocytes: randomised controlled trial in patients undergoing major surgery.

Authors:  Joost A van Hilten; Leo M G van de Watering; J Hajo van Bockel; Cornelis J H van de Velde; Job Kievit; Ronald Brand; Wilbert B van den Hout; Robert H Geelkerken; Rudi M H Roumen; Ronald M J Wesselink; Ankie W M M Koopman-van Gemert; Jan Koning; Anneke Brand
Journal:  BMJ       Date:  2004-05-13

6.  An analysis of the influence of intra-operative blood salvage and autologous transfusion on reducing the need for allogeneic transfusion in elective infrarenal abdominal aortic aneurysm repair.

Authors:  Janko Pasternak; Dragan Nikolic; Djordje Milosevic; Vladan Popovic; Vladimir Markovic
Journal:  Blood Transfus       Date:  2012-10-10       Impact factor: 3.443

7.  Intraoperative cell salvage in revision hip surgery.

Authors:  J M Herd; J J Joseph; M McGarvey; P Tsimbouri; A Bennett; R M D Meek; A Morrison
Journal:  Ann Med Surg (Lond)       Date:  2014-01-22

Review 8.  Washed cell salvage in surgical patients: A review and meta-analysis of prospective randomized trials under PRISMA.

Authors:  Patrick Meybohm; Suma Choorapoikayil; Anke Wessels; Eva Herrmann; Kai Zacharowski; Donat R Spahn
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.